| Name | Blount Discount Pharmacy Inc |
|---|---|
| Organization Name | Blount Discount Pharmacy Inc |
| Location | 129 Gill St, Alcoa, Tennessee 37701 |
| Type | Pharmacy |
| Phone | (865) 984-7704 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Breast cancer patients, their families and advocates expressed extreme disappointment at today's Food and Drug Administration (FDA) decision to remove the anti-cancer drug Avastin from the approved medication list for treatment of late stage breast cancer.
GTx, Inc. (Nasdaq: GTXI), today announced that following a planned safety review, an independent Data Safety Monitoring Board (DSMB) has recommended that the company continue as planned the pivotal Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN), a precancerous lesion of the prostate.
The digital future of the NHS will be the focus of a free Birmingham City University event next week. 'Healthcare in a Digital Age' takes place on Thursday 30 April and will see innovators Edward Miller and Robin Vickers lead discussions on the digitisation of patient information and the integration of services giving patients more control over their healthcare.
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.
› Verified 8 days ago
| NPI Number | 1316958994 |
| Organization Name | BLOUNT DISCOUNT PHARMACY INC |
| Doing Business As | BLOUNT DISCOUNT PHARMACY - GILL |
| Type | Pharmacy |
| Address | 129 Gill St, Alcoa, TN 37701 |
| Phone Number | 865-984-7704 |
News Archive
Breast cancer patients, their families and advocates expressed extreme disappointment at today's Food and Drug Administration (FDA) decision to remove the anti-cancer drug Avastin from the approved medication list for treatment of late stage breast cancer.
GTx, Inc. (Nasdaq: GTXI), today announced that following a planned safety review, an independent Data Safety Monitoring Board (DSMB) has recommended that the company continue as planned the pivotal Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN), a precancerous lesion of the prostate.
The digital future of the NHS will be the focus of a free Birmingham City University event next week. 'Healthcare in a Digital Age' takes place on Thursday 30 April and will see innovators Edward Miller and Robin Vickers lead discussions on the digitisation of patient information and the integration of services giving patients more control over their healthcare.
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.
› Verified 8 days ago
News Archive
Breast cancer patients, their families and advocates expressed extreme disappointment at today's Food and Drug Administration (FDA) decision to remove the anti-cancer drug Avastin from the approved medication list for treatment of late stage breast cancer.
GTx, Inc. (Nasdaq: GTXI), today announced that following a planned safety review, an independent Data Safety Monitoring Board (DSMB) has recommended that the company continue as planned the pivotal Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN), a precancerous lesion of the prostate.
The digital future of the NHS will be the focus of a free Birmingham City University event next week. 'Healthcare in a Digital Age' takes place on Thursday 30 April and will see innovators Edward Miller and Robin Vickers lead discussions on the digitisation of patient information and the integration of services giving patients more control over their healthcare.
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.
› Verified 8 days ago
Cvs Pharmacy #06359 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 111 S Hall Rd, Alcoa, Tennessee 37701 Phone: (865) 985-4780 | |
Walgreens #3388 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 225 N Hall Rd, Alcoa, Tennessee 37701 Phone: (865) 982-2463 | |
Wal-mart Pharmacy 10-0672 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1030 Hunters Xing, Alcoa, Tennessee 37701 Phone: (865) 984-2671 | |
Kroger Pharmacy #862 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 244 South Halls Road, Alcoa, Tennessee 37701 Phone: (865) 977-7441 | |
Blount Discount Pharmacy Inc Type: Pharmacy Location: 129 Gill St, Alcoa, Tennessee 37701 Phone: (865) 984-7704 |